Stock-based compensation expense for 2010 2010 is likely to approximate $12 to $13 million, a decrease from prior assistance of $13 to $15 million. The Company reaffirms its prior monetary guidance as follows: Gross to net sales adjustments are anticipated to approximate 12 % of gross product sales for the second half of 2010. Cost of sales are anticipated to approximate ten % of net product sales for the second half of 2010, which includes our current 8 % royalty on FOLOTYN product sales. Actual financial results for 2010 2010 will vary based on many factors, including the quantity of FOLOTYN product sales and rate of individual enrollment in FOLOTYN clinical trials that are ongoing and planned for initiation in the next half of 2010.The authors note that the existing study ‘reflects as closely as possible the conditions of daily medical practice, and as the authors point out, maximizes exterior validity and clinical relevance.’ They say that the study was limited in that the individual informed consent process was unclear and there were some patient characteristics that were not described, such as whether sufferers had previously attempted acupuncture and what their experience was. They also maintain an acupuncturist’s experience may be the most important factor in treatment final result. They conclude: ‘Given that the biologic system of acupuncture is still unclear, the analysis by Witt et al furthers our knowledge of acupuncture and increases the accumulated evidence assisting its efficacy.